Collegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Core Insights - The company has experienced significant progress in the past ten months under the new CEO, Vikram Karnani, highlighting a productive year ahead in 2025 [1][2] - A key strategic priority for the company is to maximize the growth of Jornay PM, which was acquired through the purchase of Ironshore Therapeutics, marking the company's entry into the ADHD market [2]